Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare, Inc. reported strong growth for the three months ended March 31, 2026, moving to profitability while expanding membership. Total revenues rose 33.3% year over year to $1.24 billion, driven mainly by earned premiums of $1.23 billion.
Health plan membership grew 30.9% to 284,800 members. The medical benefits ratio was 88.2%, essentially flat versus 88.4% a year earlier, indicating the company absorbed rapid growth without materially higher medical cost ratios.
Income from operations improved to $15.5 million from a loss of $5.4 million, and net income reached $11.4 million compared with a net loss of $9.4 million. Diluted net income per share was $0.05, versus a diluted loss per share of $0.05 in the prior-year period.
Adjusted metrics also strengthened: Adjusted EBITDA increased 87.6% to $37.9 million and adjusted gross profit rose 36.1% to $145.9 million. The company ended the period with $705.6 million of cash and cash equivalents, long-term debt of $323.6 million (carrying value), and total stockholders’ equity of $206.9 million.
Alignment Healthcare, Inc. reported strong results for the first quarter ended March 31, 2026, highlighted by rapid growth and a return to profitability. Total revenue reached $1,235.2 million, up 33.3% year-over-year, driven by Medicare Advantage expansion.
Health plan membership rose to approximately 284,800 members, a 30.9% increase. Adjusted gross profit was $145.9 million, up 36.1%, and income from operations was $15.5 million. The medical benefits ratio based on adjusted gross profit improved to 88.2%, reflecting better cost control.
Adjusted EBITDA was $37.9 million with a 3.1% margin, up 87.6% year-over-year, while net income was $11.4 million, compared to a $9.4 million net loss a year earlier. For 2026, the company guides to revenue of $5,160–$5,205 million and adjusted EBITDA of $138–$163 million, along with continued membership growth.
BlackRock, Inc. reports beneficial ownership of 13,596,565 shares (representing 6.7%) of Alignment Healthcare, Inc. common stock. The filing, a Schedule 13G/A, attributes these holdings to certain Reporting Business Units of BlackRock and shows sole voting power for 13,305,682 shares as of 03/31/2026.
The cover lists CUSIP 01625V104 and the filing is signed by Spencer Fleming as Managing Director on 04/24/2026.
Alignment Healthcare, Inc. has released its 2026 proxy statement, inviting stockholders to a virtual annual meeting on June 4, 2026, and seeking votes on three items: election of three Class II directors, ratification of Deloitte as auditor and a non-binding say-on-pay vote.
The proxy highlights 2025 performance, including revenue of $3.9 billion, up 46.1% year over year, health plan membership of 236,300 (up 25.0%), adjusted EBITDA of $109.9 million with a 2.8% adjusted EBITDA margin and a net loss of $1.0 million. All members were in plans rated at least 4 Stars for a second year.
The Board stresses strong governance and compensation practices: 7 of 9 directors are independent, there is a separate chair and CEO with a lead independent director, and a pay-for-performance program where most executive pay is variable, using annual cash incentives and a mix of RSUs and PSUs tied to revenue, adjusted gross profit, adjusted EBITDA and CMS Star Ratings.
Alignment Healthcare, Inc. president Dawn Christine Maroney reported an open-market sale of 30,000 shares of common stock. The shares were sold at a weighted-average price of $20.8733 per share under a pre-arranged Rule 10b5-1 trading plan.
After this transaction, Maroney directly holds 1,028,813 shares of Alignment Healthcare common stock. The sale was executed in multiple trades at prices ranging from $20.76 to $21.07 per share.
ALHC proposes the sale of 90,000 shares of Common Stock under a Rule 144 notice. The filing lists an aggregate value of $1,915,200.00 and reports 204,296,493 shares outstanding as of 04/15/2026. The excerpt also discloses recent 10b5-1 sales by Dawn Maroney totaling multiple transactions in February–March 2026, including 36,749 and 30,000 share sales.
Alignment Healthcare, Inc. director and CEO John E. Kao reported open-market sales of a total of 298,000 shares of Common Stock held indirectly through the JEK Trust, where he serves as trustee. The sales, executed under a Rule 10b5-1 plan adopted on 11/21/2025, were completed at weighted-average prices ranging from $20.26 to $21.49 per share across multiple trades. Following these transactions, the JEK Trust held 1,806,641 shares indirectly, and Kao also reported 1,784,868 shares held directly as of 04/10/2026.
Alignment Healthcare, Inc. Chief Financial Officer James M. Head reported a mandatory share sale tied to equity compensation. On April 7, 2026, he disposed of 11,100 shares of common stock at $21.08 per share to cover tax withholding obligations from vesting restricted stock units. A footnote explains this was not a discretionary trade. After this transaction, he directly holds 173,495 shares of Alignment Healthcare common stock.
Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported open-market sales of a total of 250,000 shares of Common Stock on April 7, 2026, through indirect holdings. The sales occurred at weighted-average prices of $20.67 and $21.3953 per share.
The indirectly held shares are owned by the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee. After these transactions, he continues to hold 2,104,641 shares indirectly and 1,784,868 shares directly. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025.